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1. INTRODUCTION {#ajh25511-sec-0001}
===============

Severe infections have remained an important cause of non‐relapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (HSCT).[1](#ajh25511-bib-0001){ref-type="ref"}, [2](#ajh25511-bib-0002){ref-type="ref"}, [3](#ajh25511-bib-0003){ref-type="ref"} Infections account for almost 30% of all hospital re‐admissions within the first 100 days after HSCT using myeloablative or reduced intensity conditioning.[4](#ajh25511-bib-0004){ref-type="ref"}, [5](#ajh25511-bib-0005){ref-type="ref"}

A patients\' individual risk for infections after HSCT is influenced by multiple factors including patient characteristics, transplant modalities and post‐transplant immune reconstitution. For instance, achieving a sustained neutrophil engraftment is paramount to limit the occurrence of infections caused by gram‐positive and gram‐negative bacteria or fungi, which are usually observed in the early neutropenic period.[6](#ajh25511-bib-0006){ref-type="ref"}, [7](#ajh25511-bib-0007){ref-type="ref"} Moreover, children and adults transplanted from unrelated donors and those experiencing acute graft‐vs‐host disease (GvHD) are at higher risk for bacterial and fungal infections.[8](#ajh25511-bib-0008){ref-type="ref"}, [9](#ajh25511-bib-0009){ref-type="ref"}, [10](#ajh25511-bib-0010){ref-type="ref"}, [11](#ajh25511-bib-0011){ref-type="ref"}, [12](#ajh25511-bib-0012){ref-type="ref"}, [13](#ajh25511-bib-0013){ref-type="ref"}

Viral infections or reactivations are typically observed in the post‐engraftment phase, in particular in patients with delayed T‐cell reconstitution or sustained immunosuppression due to acute or chronic GvHD.[7](#ajh25511-bib-0007){ref-type="ref"}, [14](#ajh25511-bib-0014){ref-type="ref"}, [15](#ajh25511-bib-0015){ref-type="ref"}, [16](#ajh25511-bib-0016){ref-type="ref"} The most relevant viral infections after HSCT include cytomegalovirus (CMV), adenovirus (AdV) or Ebstein‐Barr virus (EBV).

CMV reactivation and ‐disease is influenced by recipient and donor pre‐transplant serostatus and by the presence of CMV‐specific T‐cells post‐transplant.[17](#ajh25511-bib-0017){ref-type="ref"}, [18](#ajh25511-bib-0018){ref-type="ref"}, [19](#ajh25511-bib-0019){ref-type="ref"} Young age, unrelated or HLA‐mismatched donor transplantation, GvHD and delayed T‐cell reconstitution are associated with an increased incidence of ADV infections.[20](#ajh25511-bib-0020){ref-type="ref"}, [21](#ajh25511-bib-0021){ref-type="ref"}

The incidence of late opportunistic infections occurring beyond day +100 increases after HSCT from unrelated donors and in patients with advanced GvHD.[22](#ajh25511-bib-0022){ref-type="ref"} In particular, older patients, individuals with CMV reactivation or patients suffering from severe GvHD are affected by late fungal infections.[23](#ajh25511-bib-0023){ref-type="ref"}, [24](#ajh25511-bib-0024){ref-type="ref"}

The multicenter ALL‐SCT BFM 2003 trial revealed comparable event‐free survival and relapse rates in children with acute lymphoblastic leukemia (ALL). This was after transplantation from HLA‐matched sibling (MSD) or matched unrelated donors (MUD), defined by HLA match in at least nine of ten loci. However, there was a significantly higher cumulative incidence of NRM after HSCT from MUD, which was primarily attributable to severe infections (16% vs 39%; *P* \< .001).[25](#ajh25511-bib-0025){ref-type="ref"} To further elucidate the complex interplay between contributing factors and infection risk after HSCT for pediatric high‐risk ALL, a cohort of 432 children and young adults with ALL, in first or second complete remission (CR) after total body irradiation, (TBI)‐based myeloablative conditioning was analyzed. This was done retrospectively for clinically severe bacterial, viral or fungal infections at defined time points after transplantation. All patients were registered in the multicenter ALL‐SCT‐BFM 2003 trial.

2. METHODS {#ajh25511-sec-0002}
==========

This study was conducted as supplementary research project of the international multicenter ALL‐SCT‐BFM 2003 trial,[25](#ajh25511-bib-0025){ref-type="ref"} which recruited patients prospectively between 2003 and 2011. The recruitment was thereafter extended until 2013.

An approval of the local institutional review board has been obtained at each participating site and the study was performed in accordance with the Declaration of Helsinki. A written informed consent signed by the patients or their legal guardians was obtained before enrolment into the study.

Children in first or subsequent CR of ALL were eligible for study enrolment if an allogeneic HSCT was indicated according to the risk‐adapted stratification criteria of the Berlin‐Frankfurt‐Münster (BFM) Study Group.[26](#ajh25511-bib-0026){ref-type="ref"}, [27](#ajh25511-bib-0027){ref-type="ref"}, [28](#ajh25511-bib-0028){ref-type="ref"} According to the concept of the BFM study group, patients in CR1 were transplanted after minimum of three high‐risk (HR) chemotherapy‐blocks, aiming to ensure a sound molecular remission with targeted minimal residual disease (MRD) levels below 10E‐3. Patients with standard‐risk relapsed ALL were eligible for HSCT after at least five chemotherapy blocks, and patients with high‐risk relapses after at least three blocks, according to the BFM concept, aiming MRD levels below 10E‐3 before HSCT respectively. Detailed information on study design, criteria for patient and donor selection and conditioning regimens has been published previously.[25](#ajh25511-bib-0025){ref-type="ref"}

The GvHD‐prophylaxis for patients transplanted from MSD consisted of cyclosporin A (CsA) only, starting at day −1, and given at a dosage of 2 x 1.5 mg/kg BW as infusion over 2 hours each. The GvHD‐prophylaxis in patients transplanted from MUD included administration of anti‐thymocyte globulin (ATG Fresenius, given at a dose of 20 mg/kg/d on day −3, −2 and − 1), CsA as mentioned for MSD, and short‐course methotrexate (MTX 10 mg/m2; administered on days +1, +3, and + 6, followed by leucovorin rescue 24 hours later, at a dose of 15 mg/m^2^).

2.1. Definition of infection‐related complications/microbiological methods {#ajh25511-sec-0003}
--------------------------------------------------------------------------

The cohort was evaluated for severe infections (SI) graded III or higher, according to the common terminology criteria for adverse events (CTCAE).[29](#ajh25511-bib-0029){ref-type="ref"} All reported SI were then analyzed for the respective contributing pathogens, and grouped according to their appearance as follows: Infections occurring within the first 30 days after HSCT, infections between day +30 and day +100, or infections beyond day +100 after HSCT.

In symptomatic patients, an infection was classified as confirmed when at least one positive microbiological testing result was obtained. Positive results from surveillance cultures due to colonization or contamination in otherwise asymptomatic patients and asymptomatic viremias were not considered.

The onset of an infection was defined as the day when the first positive testing result was recorded. The applied methods included direct culture (bacteria and fungi), or PCR‐based methods to detect pathogen DNA (viruses) from otherwise sterile materials (whole blood, plasma, urine, cerebrospinal fluid). A central review of reported infections was not performed.

Bacterial infections were categorized as gram‐positive (GP), gram‐negative (GN) or mixed infections if different species were isolated. Confirmed invasive fungal infections were categorized as either *Aspergillus*‐ or *Candida spp* related infections or as other fungal infections including mucormycetes. For virus infections, only patients with infections graded III or IV according to CTCAE, in combination with a proven viral pathogen, were considered as clinically relevant virus infections. The evaluated viral infections included Cytomegalovirus (CMV), Ebstein‐Barr virus (EBV), Adenoviruses (AdV), Herpes simplex virus (HSV), Varicella Zoster virus (VZV), BK Virus (BKV), or other viruses.

Only the first infection of the respective pathogen in a given patient within the pre‐defined time periods was considered for the calculation of transplant outcomes, per previous publications.[22](#ajh25511-bib-0022){ref-type="ref"}, [30](#ajh25511-bib-0030){ref-type="ref"} Also, transplant‐related variables considered relevant to impact on infection risk were retrieved from our database, and put in the univariate and multivariate analysis models. The following potential risk factors were considered: Patient age, donor and recipient gender, ALL immunophenotype, remission status, time between diagnosis of ALL or relapse and HSCT, donor type, serotherapy, stem cell source, graft CD34+ cell content, recipient and donor serostatus for CMV and EBV, acute GvHD and chronic GvHD.

2.2. Supportive care and infection prophylaxis {#ajh25511-sec-0004}
----------------------------------------------

Detailed information on supportive care recommendations is provided elsewhere.[25](#ajh25511-bib-0025){ref-type="ref"} In brief, all patients were nursed in rooms with reverse isolation and high‐efficiency particulate air filters during the neutropenic period, and received a low bacterial diet.

The protocol defined no general recommendation for antibacterial or antifungal prophylaxis. However, most centers provided an antifungal prophylaxis either with azoles or amphotericin B according to their local in‐house policies.

Prophylaxis against HSV and VZV usually consisted of acyclovir starting at day +1. A CMV IgG seropositive recipient transplanted from a CMV IgG seronegative donor, thus implicating the highest risk for CMV reactivation, indicated the administration of prophylactic ganciclovir. A prospective virus‐screening for CMV, AdV and EBV in the peripheral blood usually performed on a weekly basis was available to most participating centers. If screening tests were positive, the patients received a pre‐emptive therapy with ganciclovir, cidofovir or rituximab, respectively.

Prophylaxis against pneumocystis jirovecii primarily consisted of trimethoprim/sulfamethoxazole starting at day +28.

All prophylactic therapies were carried on until the immunosuppression was stopped or adequate immunologic recovery was reached.

The institution and choice of empirical first‐line treatment of febrile neutropenia with broad‐spectrum antibiotics was left at the discretion of the attending physicians and was carried out according to local center policies.

2.3. Statistical analysis {#ajh25511-sec-0005}
-------------------------

For non‐time to event variables, the chi‐Square and Fisher\'s exact test were used to compare groups of categorical variables. Wilcoxon rank‐sum test (Kruskal‐Wallis test for more than two populations) was used for continuous variables. The cumulative incidence (CI) of infection was analyzed for the whole cohort of patients. This was also done separately for the time periods before day +30, between day +30 and + 100, and beyond day +100 after HSCT, and for the different types of infections. The CI was calculated for first episode of infection of respective type and for the respective time period. The univariate analysis was conducted according to the method of Kalbfleisch and Prentice,[31](#ajh25511-bib-0031){ref-type="ref"} groups were compared using the Gray test.[32](#ajh25511-bib-0032){ref-type="ref"} The role of risk factors for the CI of infections was further analyzed in a multivariate proportional sub‐distribution hazards model by Fine and Gray for censored data subject to competing risks.[33](#ajh25511-bib-0033){ref-type="ref"} Relapse and death without infection were defined as competing events. Acute and chronic GvHD were considered time dependent, while for non‐relapse mortality (NRM), relapses and secondary malignancies were considered competing events. All *P* values below .05 were considered significant. The statistical analyses were performed by means of the SAS version 9.4 (SAS Institute, Cary, NC).

3. RESULTS {#ajh25511-sec-0006}
==========

In total, 432 children and adolescents with ALL in first (n = 233) or second (n = 199) CR, and available data on infection‐related toxicity after myeloablative conditioning with TBI (12Gy administered in 6 fractions), and intravenous etoposide (60 mg/kg), were available for evaluation. Median age at HSCT was 10.3 years (range: 2.0‐18.5), and the donors were MSD in 129 cases, and MUD in 303 cases. Allogeneic HSCT was performed with a median at 6.6 months (range: 4.0‐17.2 months), after first diagnosis of ALL in patients with CR1 and at a median of 5.2 months (range: 2.7‐9.1 months), after diagnosis of relapse in patients with CR2. The median follow‐up from HSCT until last follow‐up evaluation was 5.4 years (range 0.04‐11.7). An overview of clinical and transplant characteristics is shown in Table [1](#ajh25511-tbl-0001){ref-type="table"}.

###### 

Transplant characteristics

  Characteristics                                                       Number (%)
  -------------------------------------------------------------------- ------------
  Diagnosis                                                            
  ALL CR1                                                               233 (54%)
  ALL CR2                                                               199 (46%)
  Recipient age                                                        
  ≤10 y                                                                 202 (47%)
  10‐15 y                                                               144 (33%)
  ≥15 y                                                                  86 (20%)
  Recipient gender                                                     
  Female                                                                151 (35%)
  Male                                                                  278 (64%)
  Data not available                                                      3 (1%)
  Donor/Recipient gender constellation                                 
  Male/Male                                                             186 (43%)
  Male/Female                                                            84 (19%)
  Female/Male                                                            92 (21%)
  Female/Female                                                          67 (16%)
  Data not available                                                      3 (1%)
  Donor                                                                
  Matched sibling donor (MSD)[a](#ajh25511-note-0002){ref-type="fn"}    129 (30%)
  Matched unrelated donor (MUD)                                         303 (70%)
  Serotherapy                                                          
  ATG Fresenius                                                         300 (69%)
  Not administered                                                      130 (30%)
  Data not available                                                      2 (1%)
  Graft type                                                           
  Bone Marrow (BM)                                                      327 (76%)
  Peripheral Blood Stem Cells (PBSC)                                    105 (24%)
  Graft composition                                                    
  CD34+ \<3 × 10^6^/kg BW                                               118 (27%)
  CD34+ \>3 × 10^6^/kg BW                                               305 (71%)
  Data not available                                                      9 (2%)
  ALL phenotype                                                        
  B‐cell precursor ALL                                                  307 (71%)
  T‐ALL                                                                  98 (23%)
  Biphenotypic ALL                                                        4 (1%)
  Data not available                                                     23 (5%)
                                                                       

Abbreviations: ALL, acute lymphoblastic leukemia; ATG, Anti‐thymocyte globulin; CR, complete remission.

Patients transplanted from MSD did not receive serotherapy with ATG.

3.1. Neutrophil engraftment {#ajh25511-sec-0007}
---------------------------

Neutrophil engraftment (NE) defined as absolute neutrophil count (ANC) of \>500 per microliter peripheral blood, was observed in 424 of 432 (98%) patients after a median time of 21 days (range: 8‐108 days). Six patients died before achieving NE and two patients never reached 500 ANC after HSCT. The median time to NE in patients transplanted from MSD was 18 days (range: 9‐45) vs 23 days for the MUD group (range: 8‐108) (*P* \< .001).

3.2. Cumulative incidences of infections at pre‐defined time periods {#ajh25511-sec-0008}
--------------------------------------------------------------------

Among 172 of 432 patients (40%) with at least one single SI reported, 464 SI were registered in total, including bacteria in 122 (26%) cases, viruses in 274 (59%), fungi in 29 cases (6%) and protozoa in one case (0.2%) respectively (Table S1). In 38 cases (8%) a pathogen was not confirmed despite an overt clinical presentation suggesting a SI. The majority of SI (56%) was classified as systemic infection due to positive testing results from blood samples. In cases of severe localized infections, the affected sites included the gastrointestinal tract (26%), the urinary tract (17%), the lungs (12%), skin or soft tissues (11%), the central nervous system (4%) or various other sites (30%). The median time to the first SI caused by any pathogen was 19 days (range: 0‐1441).

Bacterial infections were caused by GP strains in 62% (76/122); 26% (32/122) had GN infections, and 12% (14/122) had mixed or atypical bacterial infections. Gram‐positive strains included *Staphylococcus epidermidis* (22%), *Staphylococcus haemolyticus* (11%) or other coagulase‐negative *Staphylococci* (9%), *Enterococcus spp*. (16%) or *Streptococcus viridans* group (7%). The most frequently isolated GN pathogens included *Escherichia spp*. (25%), *Pseudomonas spp*. (19%), *Enterobacter spp*. (9%) and *Klebsiella spp*. (6%). Infections by GP bacteria were encountered earlier than GN infections (median onset: 15 days (range: 0‐1441) vs 87 days (range: 0‐533)). Gram‐positive infections outnumbered GN infections over all time periods as shown in Figure S1A.

Viral infections were caused by EBV in 58 (21%), CMV in 45 (17%), BKV in 56 (20%) and AdV in 38 (14%) of reported events respectively. In 77 (28%) cases, other viruses such as VZV or different Herpesviruses were found. The median onset for any viral infection was 46 days (range: 1‐1776), with infections by BKV appearing earlier than all other viruses investigated (median onset: 22 days; range: 3‐405). Figure S1B demonstrates the distribution of viral infections.

Of 29 reported fungal infections, 14 (48%) were caused by *Aspergillus spp*., 11 (38%) by *Candida spp*. and 4 (14%) by other fungi including mucormycetes. The median onset of fungal infections was 18 days (range: 1‐306). Infections by *Candida spp*. appeared earlier than infections by *Aspergillus spp*., with a median onset of 17 days (range: 1‐306) and 29 days (range: 5‐285) respectively. Fungal infections are shown in Figure S1C.

The cumulative incidence (CI) of the first SI by any pathogen was 0.27 ± 0.02 at day +30, 0.33 ± 0.02 at day +100 and 0.39 ± 0.02 1 year after HSCT. The CIs of the first reported severe bacterial, viral and fungal infections were 0.12 ± 0.02, 0.15 ± 0.02, and 0.04 ± 0.01 at day +30; 0.16 ± 0.02, 0.24 ± 0.02; 0.05 ± 0.01 at day +100 and 0.21 ± 0.02; 0.29 ± 0.02 and 0.06 ± 0.01 1 year after HSCT. The CI of infections are shown in Figures [1](#ajh25511-fig-0001){ref-type="fig"} and [2](#ajh25511-fig-0002){ref-type="fig"}.

![Cumulative incidences (CI) of the first severe infection and CI of death due to infection at day +30, +100 and 1 year after transplant for any type of infections](AJH-94-880-g001){#ajh25511-fig-0001}

![Cumulative incidences (CI) of bacterial, fungal and viral infections at day +30, +100 and 1 year after transplant](AJH-94-880-g002){#ajh25511-fig-0002}

3.3. Impact of transplant‐specific parameters on infections after HSCT: Univariate and multivariate analysis {#ajh25511-sec-0009}
------------------------------------------------------------------------------------------------------------

The donor type correlated significantly with the incidence of SI. Transplantation from MSD, compared to MUD, was associated with lower rates for any SI occurring within the first 30 days (16% vs 32%; *P* \< .001), or between day +30 and day +100 (6% vs 23%; *P* \< .001), while SI beyond day +100 were not different among the donor groups. Comparable results were obtained for different pathogens. The infection incidences within 30 days after HSCT were lower after HSCT from MSD, compared to the MUD group (8% vs 15% (*P* = .057) for bacterial infections, 8% vs 18% (*P* \< .005) for viral and 2% vs 6% (*P* = .073) for fungal infections). The incidence of viral infections in the post‐engraftment period was significantly lower in the MSD group (5% vs 19%; *P* \< .001).

Serotherapy with anti‐thymocyte globulin (ATG) as administered for HSCT from MUD was associated with higher overall infection rates within the first 30 days (31% vs 17%; *P* = .002), and between day +30 and + 100 (23% vs 7%; *P* \< .001), as compared to transplantation without ATG in the MSD group. Similar results were found for bacterial (14% vs 8%, *P* = .113), viral (18% vs 9%, *P* = .001) and fungal infections (6% vs 2%, *P* = .072) within the first 30 days. Between day +30 and day +100, significantly more viral infections were observed in the serotherapy group (19% vs 6%; *P* = .001).

The ALL phenotype, the remission status, recipient age, donor/recipient gender constellation, the graft type, graft CD34+ content, CMV‐ or EBV donor/recipient serostatus, or the time interval from diagnosis to HSCT, did not significantly impact infection rates for the defined time periods. Table [2](#ajh25511-tbl-0002){ref-type="table"} summarizes the univariate analysis (infection subtypes not included).

###### 

Risk factors associated with severe infections---univariate analysis

                                                Infections \< day 30   Infections day 30‐100   Infections \> day 100                                                             
  -------------------------------------------- ---------------------- ----------------------- ----------------------- -------- ----- ---- ---- -------- ----- ---- ------------- ------
  Patients total                                        432                     117                     27                      429   77   18            344   60   0.13 ± 0.02  
  Remission status                                                                                                                                                               
  CR1                                                   233                     58                      25              .279    232   38   16    .379    184   29   0.12 ± 0.02   .364
  CR2                                                   199                     59                      30                      197   39   20            160   31   0.14 ± 0.03  
  Recipient age                                                                                                                                                                  
  ≤10 y                                                 202                     52                      26              .819    200   37   19    .797    171   30   0.15 ± 0.03   .989
  10‐15 y                                               144                     40                      28                      144   27   19            116   20   0.10 ± 0.03  
  \>15 y                                                 86                     25                      29                      85    13   15            57    10   0.12 ± 0.04  
  Donor/Recipient gender                                                                                                                                                         
  Female/Male                                            92                     28                      30              .428    92    22   24    .086    74    18   0.15 ± 0.04   .069
  Other                                                 337                     88                      26                      334   52   16            266   40   0.12 ± 0.02  
  Data missing                                           3                       1                                               3    3                   4    2                 
  Donor type                                                                                                                                                                     
  MSD[a](#ajh25511-note-0004){ref-type="fn"}            129                     20                      16             \<.001   129   8    6    \<.001   113   18   0.11 ± 0.03   .560
  MUD                                                   303                     97                      32                      300   69   23            231   42   0.14 ± 0.02  
  CMV status                                                                                                                                                                     
  Patient+ /Donor‐                                       63                     17                      27              1.0     63    14   22    .377    52    8    0.14 ± 0.05   .704
  Other                                                 364                     98                      27                      361   63   17            287   52   0.13 ± 0.02  
  Data missing                                           5                       2                                               5                        5    0                 
  EBV status                                                                                                                                                                     
  Patient+ /Donor‐                                       49                      6                      12              .015    48    6    13    .323    45    7    0.16 ± 0.05   .702
  Other                                                 348                     99                      28                      346   67   19            264   48   0.12 ± 0.02  
  Data missing                                           35                     12                                              35    4                  35    5                 
  Serotherapy                                                                                                                                                                    
  No serotherapy                                        130                     22                      17              .002    130   9    7    \<.001   113   19   0.11 ± 0.03   .743
  ATG Fresenius                                         300                     94                      31                      297   67   23            229   14   0.14 ± 0.02  
  Data missing                                           2                       1                      50                       2    1                   2    0                 
  Graft composition                                                                                                                                                              
  ≤3 × 10^6^/kg                                         118                     32                      27              1.0     116   19   16    .775    91    15   0.13 ± 0.04   .779
  \>3 × 10^6^/kg                                        305                     82                      27                      304   55   18            247   44   0.13 ± 0.02  
  Data missing                                           9                       3                                               9    3                   6    1                 
  Graft type                                                                                                                                                                     
  BM                                                    327                     87                      27              .706    324   55   17    .381    267   48   0.14 ± 0.02   .643
  PBSC                                                  105                     30                      29                      105   22   21            77    12   0.10 ± 0.04  
  ALL phenotype                                                                                                                                                                  
  B‐cell precursor                                      307                     85                      28              .549    304   59   19    .105    254   42   0.11 ± 0.02   .386
  T‐ALL                                                  98                     26                      27                      98    14   14            73    15   0.16 ± 0.04  
  Other/n.a.                                             27                      6                      22                      27    4    15            17    3                 
  Time to HSCT                                                                                                                                                                   
  \<6 mo                                                201                     50                      25              .730    200   32   16    .787    166   32   0.15 ± 0.03   .227
  ≥6 mo                                                 194                     52                      27                      193   33   17            152   22   0.11 ± 0.03  
  Data missing                                           37                     15                                              36    12                 26    6                 

Abbreviations: ALL, acute lymphoblastic leukemia; ATG, Anti‐thymocyte globulin; BM, bone marrow; CMV, cytomegalovirus; CR, complete remission; EBV, Ebstein‐Barr virus; GvHD, graft‐vs‐host disease; MSD, matched sibling donor; MUD, matched unrelated donor; n.a., not available; PBSC, peripheral blood stem cells.

Patients transplanted from MSD did not receive serotherapy with ATG Fresenius.

In our multivariate regression model, the donor type significantly correlated with SI. Transplantation from MUD was associated with any SI during the pre‐engraftment period (HR: 2.57; 95% CI: 1.52‐4.33; *P* \< .001), and with any SI between day +30 and + 100 (HR: 2.91; 95% CI: 1.28‐6.61; *P* = .011).

Patients with documented SI before day +30, or day +100, carried a significant risk of experiencing another SI in the subsequent observation period (HR: 7.94; 95% CI: 4.55‐13.84; *P* \< .001 for infections between day +30 and + 100; HR: 1.96; 95% CI: 1.09‐3.53; *P* = .024 for infections after day +100).

Chronic GvHD was an independent risk factor for any SI beyond day +100 (HR: 2.57; 95% CI: 1.43‐4.63; *P* = .002), and we found a non‐significant trend for any SI occurring between day +30 and + 100 in patients with acute GvHD grade 3 or 4 (HR: 1.56; 95% CI: 0.91‐2.69; *P* = .108). The multivariate analysis is shown in Table [3](#ajh25511-tbl-0003){ref-type="table"}.

###### 

Risk factors associated with severe infections---multivariate analysis

                                     Infections \< day 30   Infections day 30‐100   Infections \> day 100                                                               
  --------------------------------- ---------------------- ----------------------- ----------------------- -------- ------ ------ ------- -------- ------ ------ ------ ------
  Remission status                                                                                           .162                           .800                         .558
  CR2 vs CR1                                 1.31                   0.90                    1.90             .162    1.07   0.65   1.74     .800    1.18   0.67   2.08   .558
  Recipient age                                                                                              .363                           .972                         .972
  10‐15 y vs ≤10 y                           1.24                   0.82                    1.89             .307    1.02   0.61   1.72     .939    0.95   0.53   1.73   .871
  \>15 y vs ≤10 y                            1.41                   0.85                    2.33             .188    0.94   0.46   1.90     .856    0.91   0.39   2.12   .827
  Donor/Recipient gender                                                                                     .230                           .140                         .138
  Female/Male vs other                       1.31                   0.85                    2.02             .230    1.52   0.87   2.64     .140    1.54   0.87   2.74   .138
  Donor                                                                                                     \<.001                          .011                         .574
  MUD vs MSD                                 2.57                   1.52                    4.33            \<.001   2.91   1.28   6.61     .011    1.20   0.64   2.24   .574
  CMV status donor/patient                                                                                   .799                           .416                         .731
  Negative/Positive vs Other                 0.93                   0.53                    1.63             .799    1.32   0.67   2.61     .416    1.15   0.53   2.51   .731
  Graft composition                                                                                          .755                           .446                         .479
  \>3 × 10^6^/kg vs ≤3 × 10^6^/kg            1.07                   0.70                    1.62             .755    1.26   0.70   2.26     .446    1.24   0.69   2.22   .479
  Graft type                                                                                                 .376                           .708                         .412
  BM vs PB unmanipulated                     1.22                   0.79                    1.89             .376    1.12   0.62   2.01     .708    1.38   0.64   2.97   .412
  Infection prior day 30                                                                                                                   \<.001                       
  yes vs no                                  n.a.                   n.a.                    n.a.             n.a.    7.94   4.55   13.84   \<.001   n.a.   n.a.   n.a.   n.a.
  Infection prior day 100                                                                                                                                                .024
  yes vs no                                  n.a.                   n.a.                    n.a.             n.a.    n.a.   n.a.   n.a.     n.a.    1.96   1.09   3.53   .024
  Acute GVHD grade 3‐4                                                                                                                      .108                        
  yes vs no                                  n.a.                   n.a.                    n.a.             n.a.    1.56   0.91   2.69     .108    n.a.   n.a.   n.a.   n.a.
  Chronic GVHD                                                                                                                                                           .002
  yes vs no                                  n.a.                   n.a.                    n.a.             n.a.    n.a.   n.a.   n.a.     n.a.    2.57   1.43   4.63   .002

Abbreviations: ALL, acute lymphoblastic leukemia; ATG, Anti‐thymocyte globulin; BM, bone marrow; CMV, cytomegalovirus; CR, complete remission; GvHD, graft‐versus‐host disease; MSD, matched sibling donor; MUD, matched unrelated donor; PB, peripheral blood stem cells; n.a. not available.

A subgroup analysis for different pathogens (detailed data not shown) revealed similar results: Viral infections were encountered more often in the MUD group, both early (HR: 2.66; 95% CI: 1.30‐5.41; *P* = .007) and between day +30 and + 100 after HSCT (HR: 3.89; 95% CI: 1.62‐9.32; *P* = .002). Furthermore, bacterial infections (HR: 2.24; 95% CI: 1.03‐4.85; *P* = .041) and fungal infections (HR: 4.06; 95% CI: 0.96‐17.18; *P* = .057), were observed more frequently in the pre‐engraftment period after HSCT from MUD.

3.4. Lethal infections/impact on non‐relapse mortality {#ajh25511-sec-0010}
------------------------------------------------------

Eleven patients died due to severe infections, one of them after HSCT from MSD and 10 after MUD transplantation. The reported primary causes of death were bacteria in three cases, viruses in seven cases, and a fungal pathogen in one case, respectively. Lethal infections occurred within the pre‐engraftment phase in six cases, between day +30 and + 100 in four cases, and after day +100 in one patient. The calculated 1‐year cumulative incidence of death due to infection was 0.03 ± 0.01 (Figure [1](#ajh25511-fig-0001){ref-type="fig"}).

4. DISCUSSION {#ajh25511-sec-0011}
=============

Severe infections (SI) are encountered in up to 60% of patients receiving HSCT. They remain a major cause of non‐relapse mortality after allografting for malignant and non‐malignant diseases in adults.[1](#ajh25511-bib-0001){ref-type="ref"}, [34](#ajh25511-bib-0034){ref-type="ref"}, [35](#ajh25511-bib-0035){ref-type="ref"}, [36](#ajh25511-bib-0036){ref-type="ref"} However, published data are difficult to compare. The investigated cohorts often differ significantly in terms of transplant modalities, underlying disease, age or prophylactic measures. We evaluated a cohort of 432 children and young adults with ALL after HSCT for the occurrence of SI. They received a TBI‐based myeloablative allogeneic transplantation from MSD or MUD within the multicenter ALL‐BFM SCT 2003 trial. The SI with positive microbiologic testing results were reviewed. A total of 172 patients (40%) experienced at least one SI.

The CI of the first bacterial SI was 0.12 ± 0.02 at day +30, 0.16 ± 0.02 at day+100, and 0.21 ± 0.02 one year after HSCT. Gram‐positive infections (62%) dominated over GN infections (26%) across all time periods, and were predominantly encountered in the pre‐engraftment period, as shown by others.[34](#ajh25511-bib-0034){ref-type="ref"}, [35](#ajh25511-bib-0035){ref-type="ref"}, [37](#ajh25511-bib-0037){ref-type="ref"} Coagulase‐negative staphylococci, accounting for 42% of all GP infections, were the most frequent isolates in our cohort, in line with previous observations.[9](#ajh25511-bib-0009){ref-type="ref"}, [12](#ajh25511-bib-0012){ref-type="ref"}, [37](#ajh25511-bib-0037){ref-type="ref"} However, a contamination or colonization seems conceivable in several of these cases. Gram‐negative infections were primarily caused by *Escherichia spp*. or *Pseudomonas spp*., accounting for approximately 20% of all GN isolates each. Other investigators reported infection rates up to 37% for *E. coli* and 26% for *Pseudomonas*.[22](#ajh25511-bib-0022){ref-type="ref"}, [35](#ajh25511-bib-0035){ref-type="ref"}, [37](#ajh25511-bib-0037){ref-type="ref"} Of note, our cohort did not routinely receive prophylactic fluoroquinolones, which was a common practice among many adult transplant centers during the last decade, to lower the burden of GN strains.[38](#ajh25511-bib-0038){ref-type="ref"} Severe kinds of bacterial infections accounted for 27% of all lethal infections, and occurred within the first 100 days in most cases.

The early neutropenic period is not only critical for the development of bacterial but also for fungal infections, although a shift towards later fungal infections has been reported during recent years.[7](#ajh25511-bib-0007){ref-type="ref"}, [11](#ajh25511-bib-0011){ref-type="ref"}, [39](#ajh25511-bib-0039){ref-type="ref"}, [40](#ajh25511-bib-0040){ref-type="ref"} The CI of the first fungal SI in our cohort was 0.04 ± 0.01 at day +30, 0.05 ± 0.01 at day+100 and 0.06 ± 0.01 1 year after HSCT. The majority of severe fungal infections were caused by *Aspergillus spp*. (48%) and *Candida* (38%), both primarily observed in the pre‐engraftment phase. Other fungal pathogens, such as mucormycetes, were rarely detected. Infections by *Aspergillus spp*. were fatal in 7% of reported cases. Altogether, fungal infections accounted for 10% of the eleven reported fatalities, which is in contrast to Srinivasan et al., who reported more than 50% of all fatal infections being caused by molds in a similar pediatric cohort.[22](#ajh25511-bib-0022){ref-type="ref"}

The comparably low overall rate of invasive fungal infections in our study might have various reasons. Most centers provided a primary antifungal prophylaxis until adequate immune reconstitution was reached. The immunosuppression in patients without acute GvHD was tapered as soon as day +60 on, to minimize the relapse risk in our cohort, which might have prevented late fungal infections. Also, the low overall acute GvHD rates within the study population (acute GvHD grade 2 or 3: 11% for MSD and 10% for MUD). Could have limited fungal infections after the engraftment period. It has been shown by others that GvHD per se is associated with invasive aspergillosis, primarily due to substantial immunosuppression including corticosteroids.[11](#ajh25511-bib-0011){ref-type="ref"}

Systemic viral infections have been reported in up to 60% of children after HSCT.[30](#ajh25511-bib-0030){ref-type="ref"} Viremia is most frequently detected after the engraftment period.[41](#ajh25511-bib-0041){ref-type="ref"} Although not exclusively confined to the post‐engraftment period, viral infections in our cohort were mainly observed during this phase. As shown in Figure S1B, severe EBV and CMV infections usually occurred after day +30, whereas AdV infections were equally distributed between pre‐engraftment and post‐engraftment. Most viral infections were observed approximately 35 to 40 days after HSCT, except BKV, which was detected earlier. Severe viral infections were reported as the primary cause of death in 64% of all patients with fatal infections.

The donor type has been identified as an important risk factor for SI in both adults[9](#ajh25511-bib-0009){ref-type="ref"}, [10](#ajh25511-bib-0010){ref-type="ref"}, [34](#ajh25511-bib-0034){ref-type="ref"} and children.[42](#ajh25511-bib-0042){ref-type="ref"} So, HSCT from alternative donors conveys a higher risk for bacterial or fungal infections, as compared to transplantation from siblings. In line with these observations, we found more SI in our cohort of children with ALL after HSCT from MUD, compared to MSD. Transplantation from MUD was associated with any type of SI in the pre‐engraftment period, and with any SI between day +30 and + 100. Furthermore, fatal infections were more often encountered after HSCT from MUD.

The observed increase of infections after MUD HSCT could be explained by differences in transplant modalities. In our cohort, almost all patients transplanted from MUD received a GvHD prophylaxis with ATG, and short‐course methotrexate in addition to CsA, both of which impact on hematopoietic engraftment and immune reconstitution.

Methotrexate is well known to interfere with granulocyte recovery after HSCT.[43](#ajh25511-bib-0043){ref-type="ref"} A prolonged neutropenia increases the risk, especially for severe bacterial or fungal infections.[7](#ajh25511-bib-0007){ref-type="ref"} Patients transplanted from MSD recovered their neutrophils significantly faster, compared to recipients of MUD grafts, as reported previously.[44](#ajh25511-bib-0044){ref-type="ref"} This might have influenced infection rates in the pre‐engraftment period after HSCT from unrelated donors. Both, bacterial and fungal infections were observed more often after HSCT from MUD.

In‐vivo T‐cell depletion with ATG additionally seems to increase the infection risk. It has been demonstrated, that ATG impairs the T‐cell reconstitution,[45](#ajh25511-bib-0045){ref-type="ref"}, [46](#ajh25511-bib-0046){ref-type="ref"} which in turn might facilitate virus reactivations.[47](#ajh25511-bib-0047){ref-type="ref"} In line, significantly more viral infections were observed before day +30, or between day +30 and +100 after HSCT from MUD, compared to transplantation from MSD, who did not receive ATG. Although it is impossible for our cohort to prove that the observed effect in patients transplanted from MUD is directly related to the administration of ATG, an association seems at least conceivable. Unfortunately, data on T‐cell immune reconstitution is not available.

Patients with GvHD often require an intensified immunosuppression, including high‐dose corticosteroids, which make them susceptible to opportunistic infections.[48](#ajh25511-bib-0048){ref-type="ref"}, [49](#ajh25511-bib-0049){ref-type="ref"} Children in our cohort with acute GvHD grade 3 or 4, had a non‐significant trend towards SI occurring beyond day +30, as reported by others.[22](#ajh25511-bib-0022){ref-type="ref"}, [50](#ajh25511-bib-0050){ref-type="ref"}, [51](#ajh25511-bib-0051){ref-type="ref"} Moreover, children with chronic GvHD particularly were at risk for any type of SI occurring beyond day +100. That confirms the data by Srinivasan, who identified chronic GvHD as an independent risk factor for bacterial and fungal infections beyond day +100 after HSCT in a similar cohort.[22](#ajh25511-bib-0022){ref-type="ref"}

We are aware that our study has several limitations, which are the heterogeneous practice for antimicrobial prophylaxis, pre‐emptive or empiric treatment of infections, the lack of standardized microbiological testing methods for all participating centers, and missing information on antimicrobial resistance of pathogens. Detailed information on pre‐transplant chemotherapy, or on asymptomatic viral reactivations after HSCT, was not available. Furthermore, the cohort was too small for a thorough subgroup analysis.

In conclusion, our study confirms the correlation between donor type and infection rates in a cohort of 432 children and adolescents, after TBI‐based myeloablative HSCT for ALL. Transplantation from MUD was associated with an increased risk for any type of SI in the pre‐engraftment period, and for viruses between day +30 and + 100 after HSCT. This could be explained by an intensified GvHD prophylaxis consisting of serotherapy with ATG and administration of methotrexate for recipients of MUD transplants.
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**Figure S1** Numbers and subtypes of the first reported bacterial (A), viral (B) and fungal infections (C) within defined time periods after HSCT.

**Table S1.** Reported infections

###### 

Click here for additional data file.
